Apnimed, Inc. (APMD) Stock Ticker
APMD right now
Market factors today
Unlock the full APMD picture
About Apnimed, Inc.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
APMD stock facts
| Ticker symbol | APMD |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $839.9M |
| CEO | Kevin R. Lind |
| Employees | 65 |
| Headquarters | Cambridge, MA, US |
| IPO date | 2026-07-29 |
| Website | apnimed.com |
What you can see for APMD on Tickr
Live APMD price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the APMD report.
Rankings
FAQ
What is the ticker symbol for Apnimed, Inc.?
The ticker symbol for Apnimed, Inc. is APMD, listed on the NASDAQ.
What is APMD?
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in…